Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 12,07700Cr 7.58TCr 6.88TCr 6.36TCr 5.74TCr 11TCr 7,08300Cr 11TCr 77TCr 30TCr 3,82200Cr 28TCr 28TCr P/E 2026 *
23.7x
P/E 2027 * 20.9x
Enterprise Value 11,16000Cr 7.01TCr 6.36TCr 5.88TCr 5.3TCr 10TCr 6,54600Cr 10TCr 71TCr 28TCr 3,53200Cr 26TCr 26TCr EV / Sales 2026 *
8x
EV / Sales 2027 * 7.15x
Free-Float
38.12%
Yield 2026 *
1.84%
Yield 2027 * 2.08%
1 day-1.83%
1 week+0.84%
Current month+5.63%
1 month+13.77%
3 months+5.24%
6 months-8.61%
Current year-12.58%
1 week 7,011
Extreme 7011
7,506
1 month 6,269
Extreme 6269
7,506
Current year 5,974
Extreme 5974
10,700
1 year 5,974
Extreme 5974
10,700
3 years 4,572
Extreme 4572
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.333333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%+0.84%-13.18%+47.66% 7.58TCr
-1.13%-1.17%+38.55%+139.23% 1,26100Cr
-1.36%-0.74%+39.64%+86.06% 67TCr
-0.59%-0.36%+25.14%+111.73% 52TCr
-0.76%+1.10%+41.43%+70.96% 39TCr
-0.75%-3.16%+54.39%+40.90% 35TCr
-1.83%-0.89%+26.00%+58.48% 30TCr
-1.65%-0.59%+1.55%+34.52% 28TCr
-0.95%-1.57%+34.01%+72.55% 25TCr
+1.60%-0.36%+37.21%+125.66% 21TCr
Average -0.93%-0.06%+28.47%+78.78% 43TCr
Weighted average by Cap. -0.99%-0.49%+34.12%+94.83%

Financials

2026 *2027 *
Net sales 1,39600Cr 876.11Cr 795.33Cr 734.69Cr 662.8Cr 1.25TCr 82TCr 1.3TCr 8.85TCr 3.5TCr 44TCr 3.29TCr 3.22TCr 1,52700Cr 958.74Cr 870.35Cr 803.99Cr 725.32Cr 1.37TCr 90TCr 1.42TCr 9.69TCr 3.83TCr 48TCr 3.6TCr 3.52TCr
Net income 51TCr 319.99Cr 290.49Cr 268.34Cr 242.09Cr 457.02Cr 30TCr 474.52Cr 3.23TCr 1.28TCr 16TCr 1.2TCr 1.18TCr 58TCr 362.9Cr 329.44Cr 304.32Cr 274.55Cr 518.3Cr 34TCr 538.15Cr 3.67TCr 1.45TCr 18TCr 1.36TCr 1.33TCr
Net Debt -92TCr -575.33Cr -522.28Cr -482.46Cr -435.25Cr -821.7Cr -54TCr -853.15Cr -5.81TCr -2.3TCr -29TCr -2.16TCr -2.11TCr -1,16400Cr -730.73Cr -663.36Cr -612.78Cr -552.82Cr -1.04TCr -68TCr -1.08TCr -7.38TCr -2.92TCr -37TCr -2.74TCr -2.68TCr
Projected Income Statement - Annual - Chugai Pharmaceutical Co., Ltd.
Logo Chugai Pharmaceutical Co., Ltd.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Employees
5,104
Date Price Change Volume
18/26/18 JP¥7,206.00 -1.83% 19,07,800
17/26/17 JP¥7,340.00 -0.54% 26,79,300
16/26/16 JP¥7,380.00 +2.77% 27,84,700
13/26/13 JP¥7,181.00 +0.46% 20,47,000
12/26/12 JP¥7,148.00 +0.03% 24,23,700
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Chugai Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
7,340.00JPY
Average target price
8,393.33JPY
Spread / Average Target
+14.35%
  1. Stock Market
  2. Stocks
  3. 4519 Stock